SynthesisFrontiers in pediatrics2021
The Efficacy and Safety of Rituximab for Childhood Steroid-Dependent Nephrotic Syndrome: A Systematic Review and Meta-Analysis.
Synthesis in Frontiers in pediatrics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Evaluation of the comparative efficacy and safety of obinutuzumab and other follow-up strategies after rituximab failure in refractory nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2026Article
- Summary for clinicians: ERS guidelines on pulmonary alveolar proteinosis.Breathe (Sheffield, England) · 2025Review
- Rituximab-associated adverse events in nephrotic syndrome: A systematic review and meta-analysis.Heliyon · 2025Article
- Efficacy and safety of rituximab in children with steroid-dependent or frequently relapsing nephrotic syndrome: a meta-analysis of randomized controlled trials.Archives of medical science : AMS · 2025Review
- Rituximab Administration to Treat Nephrotic Syndrome in Children: 2-Year Follow-Up.Biomedicines · 2024Article
- Difficult-to-Treat Nephrotic Syndrome in Childhood-Global Depletion of B-Cells.Kidney international reports · 2024Article
- Rituximab treatment for refractory nephrotic syndrome in adults: a multicenter retrospective study.Renal failure · 2023Article
- Repetitive administration of rituximab can achieve and maintain clinical remission in patients with MCD or FSGS.Scientific reports · 2023Article
- Identification of Risk Factors for Relapse following Rituximab Therapy in Children with Steroid-Sensitive Nephrotic Syndrome.Kidney diseases (Basel, Switzerland)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.